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Human b-glucuronidase, due to low intrinsic immu-
nogenicity in humans, is an attractive enzyme for
tumor-specific prodrug activation, but its utility is
hindered by low activity at physiological pH. Here
we describe the development of a high-throughput
screening procedure for enzymatic activity based
on the stable retention of fluorescent reaction prod-
uct in mammalian cells expressing properly folded
glycoproteins on their surface. We utilized this pro-
cedure on error-prone PCR and saturation mutagen-
esis libraries to isolate b-glucuronidase tetramers
that were up to 60-fold more active (kcat/Km) at pH
7.0 and were up to an order of magnitudemore effec-
tive at catalyzing the conversion of two structurally
disparate glucuronide prodrugs to anticancer
agents. The screening procedure described here
can facilitate investigation of eukaryotic enzymes re-
quiring posttranslational modifications for biological
activity.
INTRODUCTION
Chemotherapy is an important treatment modality for advanced
cancers, but systemic toxicity typically limits therapeutic effi-
cacy. Antibody- (Bagshawe et al., 1988; Senter et al., 1988)
and gene-directed enzyme prodrug therapy (Chen et al., 1994)
(ADEPT and GDEPT) are approaches to increase the therapeutic
index of cancer chemotherapy. ADEPT and GDEPT employ an-
tibody-targeted or gene-expressed enzymes to preferentially
activate nontoxic antineoplastic drugs at cancer cells, thereby
sparing normal tissues from high concentrations of toxic drug.
Although microbial and viral enzymes are largely utilized for tar-
geted prodrug activation, the development of strong immune re-
sponses against foreign proteins can rapidly hinder therapeutic
effectiveness (Napier et al., 2000; Sharma et al., 1992). The utili-
zation of human enzymes is therefore highly desirable to mini-
mize immune responses and allow multiple rounds of treatment.
b-glucuronidase (bG, EC 3.2.1.31) is an attractive enzyme for
ADEPT and GDEPT because both mammalian and bacterial ho-
mologs exist. A variety of glucuronide prodrugs have demon-
strated impressive antitumor activity in diverse tumor models
(de Graaf et al., 2002). Although many studies have employed
Escherichia coli b-glucuronidase (ebG) to activate glucuronide
prodrugs at cancer cells because of the high specific activity of
the bacterial enzyme (Chen et al., 2001, 2007; Cheng et al.,
1999b; Wang, 1992), development of human b-glucuronidase
(hbG) therapies is desirable to minimize immune responses in
patients. hbG is sequestered in lysosomes and is therefore
largely inaccessible to membrane-impermeable glucuronides,
minimizing the problem of systemic activation of prodrugs by en-
dogenous enzymes (Cheng et al., 1999a). As an acid hydrolase,
hbGdisplaysmaximum activity at pH 4.0, but relatively low activ-
ity at neutral pH (Chen et al., 2007). Translation of glucuronide
prodrug therapy to the clinic could be facilitated by generating
hbG variants that more efficiently hydrolyze prodrugs under the
physiological conditions present in tumors.
The pH profile of enzymes has been altered by substituting
specific amino acids that directly (Kim et al., 2006) or indirectly
(Makde et al., 2006) contact substrates as well as by changing
amino acids on the enzyme surface (Russell and Fersht, 1987).
However, it is difficult to rationally alter the pH profile of an en-
zyme with retention of catalytic activity. Directed evolution, on
the other hand, is an extremely versatile and powerful method
to modify protein properties without a priori detailed knowledge
of protein structure-function relationships (Kaur and Sharma,
2006).
Whereas most directed evolution has been performed in bac-
teria, many eukaryotic proteins require posttranslational modifi-
cations such as glycosylation for proper folding and catalytic ac-
tivity. For example, hbG is expressed as a tetramer composed of
four identical monomeric subunits of 629 amino acids, each pos-
sessing four N-linked oligosaccharides that are required for
proper protein folding (Shipley et al., 1993). Furthermore, assay
of hbG activity at defined pH values is difficult due to cell-to-
cell variations in lysosomal pH (Anderson and Orci, 1988). In
the present study, we solved these problems by tethering hbG
on the surface of mammalian cells to allow assay of properly gly-
cosylated and active enzyme under defined conditions. We
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high-throughput flow cytometric sorting allows successful isola-
tion of hbG variants with enhanced activity at neutral pH.
RESULTS
Development of a Mammalian Cell-Surface-Tethered
Enzyme Screening System
We tethered human bG (hbG) and mouse bG (mbG) on the sur-
face of mammalian cells by fusing the cDNA for the respective
bG genes to the juxtamembrane Ig-like extracellular domain,
transmembrane domain, and cytoplasmic tail of murine B7-1
(Chen et al., 2007; Cheng and Roffler, 2008). mbGwas employed
for some assays because it displays about 3-fold greater enzy-
matic activity than hbG at pH 7.0, allowing better sensitivity for
initial method development. hbG was stably expressed with re-
tention of enzymatic activity on 3T3 fibroblasts, as determined
by surface immunofluorescence staining with a FITC-labeled
Figure 1. Characterization of Membrane-
Tethered bG
(A) 3T3 cells that stably expressed membrane-
tethered hbG were treated with 250 (bold solid
line), 125 (dashed line), 62.5 (dotted line), or 0 (reg-
ular solid line) mg/ml trypsin for 5 min at 37C be-
fore 100 mM ELF-97 b-D-glucuronide was added
to the cells at pH 6.0 for 15 min at 37C. Surface
hbG expression was detected by staining with
7G8-FITC. The cells were analyzed for FITC (sur-
face hbG expression) or ELF-97 alcohol (hbG en-
zymatic activity) fluorescence on a flow cytometer.
Negative control (3T3) cells are shown in gray.
(B) CT26/mbG cells were stained with 25 mM
ELF-97 b-D-glucuronide at pH 6.0 (solid line) or
pH 7.0 (dashed line) for 5min at room temperature.
Negative control CT26 cells were stained with
ELF-97 b-D-glucuronide at pH 6 (gray).
(C) EJ and EJ/mbG cells were seeded separately
(left and middle panels) or mixed (right panel) on
cover slides before staining for bG activity (with
100 mM ELF-97 b-D-glucuronide, green) and
membrane-anchored mbG expression (with bio-
tin-labeled goat anti-HA followed by streptavidin-
labeled rhodamine, red). Cells were observed un-
der a fluorescence microscope equipped with
a CCD detector.
(D) CT26 and CT26/mbG cells were stained indi-
vidually or in a 50/50 mixture for bG activity
(25 mM ELF-97 b-D-glucuronide [pH 6.0] at room
temperature for 5 min) and mbG protein expres-
sion (mAb 7G7 and goat anti-rat-FITC) and then
analyzed by FACS.
anti-hbG antibody (7G8-FITC) and by
hydrolysis of the substrate ELF-97 b-D-
glucuronide to ELF-97 alcohol (Telford
et al., 2001), a fluorescent product that
remained associated with the cells (Fig-
ure 1A). Trypsin proteolysis of cell-sur-
face proteins reduced hbG expression
and enzymatic activity in parallel (Fig-
ure 1A), demonstrating that membrane-tethered hbG was
responsible for hydrolysis of ELF-97 b-D-glucuronide. The enzy-
matic activity of membrane-tethered mbG depended on the
extracellular pH, allowing convenient control of the enzyme
environment (Figure 1B). Cells expressing membrane-tethered
mbG were clearly distinguishable from wild-type (WT) cells un-
der fluorescence illumination after staining mixed-cell popula-
tions with ELF-97 b-D-glucuronide (Figure 1C). To determine
whether high-throughput flow cytometric sorting of cells based
on relative bG activity was feasible, a mixture of WT cells and
cells expressing membrane-tethered mbG was first stained
with rat anti-mbG antibody followed by goat anti-rat FITC
conjugate and then incubated with ELF-97 b-D-glucuronide.
Two discrete populations of cells could be clearly separated
(Figure 1D), demonstrating that enzymatically generated
ELF-97 alcohol remained associated with cells expressing
membrane-tethered bG during the staining and analysis
procedure.
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at Neutral pH
Based on these results, we developed a robust high-throughput
fluorescence-activated cell-sorting method to isolate hbG
mutants with enhanced activity at neutral pH (Figure 2A). We em-
ployed error-prone PCR to generate a cDNA library (EP1 library)
with a diversity of 5 3 106 containing an average of 4.5 amino
acid mutations per hbG gene. 3T3 fibroblasts were infected at
low MOI (multiplicity of infection; 0.6 cfu/cell) with a VSV-G
pseudotyped retroviral virus library to generate 107 indepen-
dent 3T3 clones. After selection in G418, viable cells were
stained with 7G8-FITC (anti-hbG-FITC conjugate) and incubated
with ELF-97 b-D-glucuronide before they were sorted on a flow
cytometer for enhanced bG activity relative to hbG expression
levels. The first round of screening was performed at pH 5.0 to
enrich for rare cells displaying enhanced bG enzymatic activity
at slightly elevated pH (Figure 2B, left panel). Selected cells
(0.5% of the total cell population) were cultured to expand their
numbers and then resorted two additional times after immuno-
fluorescence staining for hbG expression with 7G8-FITC and
labeling bG activity with ELF-97 b-D-glucuronide at pH 6.5 to
isolate cells displaying enhanced surface enzymatic activity at
elevated pH. The sorted population displayed increased
enzymatic activity as compared to cells expressing mem-
brane-tethered WT hbG (Figure 2B, right panel). The sorted pop-
ulation also exhibited enhanced enzyme activity at both pH
5.0 and pH 6.5, indicating that enzyme variants with a broader
pH profile can be isolated by applying selection pressure based
on reaction pH (Figure 2C). Sequencing the hbG gene in 12 in-
dividual cell clones revealed multiple mutations. However, all
hbG variants had mutations at position 545 (50% T/A and
50% T/S). To determine the effect of amino acid substitutions
at position 545 on enzyme activity, the single amino acid mu-
tants T545A (E1-A), T545G (E1-G), T545S (E1-S), and T545Y
(E1-Y) were generated and the corresponding enzymes were
purified from the culture medium of stably transfected fibro-
blasts. Assay for enzymatic activity at pH 7.0 with the substrate
p-nitrophenol b-D-glucuronide revealed that E1-G and E1-A
displayed about 2.5-fold greater activity than WT hbG, E1-S
exhibited about 1.5-fold greater activity, and E1-Y was almost
inactive (data not shown). Thus, single amino acid changes
can affect hbG activity at neutral pH. We employed the E1-G
(50%) and E1-A (50%) variants as starting material to generate
an error-prone cDNA library (EP2) with 5 3 106 members
containing an average of 2.6 amino acid mutations per hbG
gene. Independent 3T3 clones (5 3 107) were immunofluores-
cence stained with 7G8-FITC and reacted with ELF-97 b-D-glu-
curonide at pH 7.0. Sixteen individual cell clones were isolated
after three rounds of sorting and the hbG genes were
sequenced. All of the isolated hbG genes possessed identical
amino acid substitutions at position 255 (L/Q) and 545 (T/
G) with variable substitutions at other positions. One high-
activity variant, termed E2-20, was selected for further
examination (Table 1).
To help differentiate between beneficial and null mutations in
the hbG variants, hbG cDNA isolated from the sorted EP1 library
(30%) was shuffled with theWT hbGgene (70%) to breed out null
mutations. The shuffled backcross library was then expressed
on 3T3 fibroblasts and screened with 7G8-FITC and ELF-97
b-D-glucuronide at pH 7.0. After one round of flow cytometric
sorting, individual cell clones were isolated and the hbG gene
was sequenced. Among 13 single-cell clones, amino acid
changes at positions 545, 595, and 599 were consistently asso-
ciated with increased hbG activity at neutral pH values.
Figure 2. High-Throughput FACS Screening at Defined pH
(A) The transgene codes for the immunoglobulin k chain signal peptide (SP), an
HA epitope (HA), hbG fused to the first extracellular domain (spacer), trans-
membrane domain (TM), and cytoplasmic tail (CT) of the murine B7-1 antigen.
(1) Mutations were introduced in the hbG gene by error-prone PCR, DNA shuf-
fling, or saturation mutagenesis. (2) hbG transgenes were retrovirally infected
in 3T3 cells to generate a membrane-tethered hbG cell library. (3) Surface
expression of hbG allowed adjustment of reaction pH for screening. The cell
library was reacted with ELF-97 b-D-glucuronide to accumulate fluorescent
ELF-97 alcohol in cells. (4) Cells exhibiting higher bG activity were collected
and expanded for further analysis.
(B) 3T3 cells expressing membrane-tethered WT (blue) or mutant (red) hbG
were reacted with 25 mM ELF-97 b-D-glucuronide for 15 min at room temper-
ature and then stained with 7G8-FITC. Cells that exhibited higher bG activity at
pH 5 were isolated by FACS (left panel). After two additional rounds of sorting
at pH 6.5, a population of cells with higher bG activity at pH 6.5 was isolated
(right panel).
(C) 3T3 fibroblasts expressing WT hbG (solid line), or unsorted (dotted line)
or sorted (dashed line) collections of hbG variants, were exposed to 25 mM
ELF-97 b-D-glucuronide at pH 5 (left panel) or pH 6.5 (right panel) for 15 min
at room temperature. Negative control (3T3) cells are shown in gray.
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To further examine the influence of varying the amino acids at
positions 545, 595, and 599 on the catalytic activity of hbG, we
employed saturation mutagenesis to generate a small library
(105 cell clones) covering all possible combinations of amino
acids at these three sites. The library was screened by two
rounds of cell sorting at pH 7.0. Among 14 single-cell clones dis-
playing high activity, seven different amino acids (all nonnega-
tively charged) appeared at position 595. Furthermore, 79% of
the hbG variants had serine at position 545, and 13 of 14 clones
contained amino acids with hydrophobic side groups (28.5%
leucine, 28.5% isoleucine, and 43% phenylalanine) at position
599. Two variants (S2 and S28 in Table 1) were selected for fur-
ther analysis.
Characterization of bG Variants
Table 1 summarizes the mutations present in five membrane-
tethered hbG variants which displayed 20- to 115-fold greater
enzyme activity than WT hbG for ELF-97 b-D-glucuronide at
pH 7.0. The amount of hbG protein expressed by each cell line
varied as determined by immunoblot analysis (see Figure S1A
available online). There was a strong linear correlation between
total hbG expression level (as determined by hbG band intensity
on the immunoblot in Figure S1A) and surface hbG levels, as de-
termined by immunofluorescence staining of hbG followed by
flow cytometric analysis (Figure S1B). This confirms that immu-
nofluorescence staining allows convenient normalization of en-
zyme activities for differences in hbG expression levels.
To further characterize the hbG variants, we purified soluble
hbG enzymes from 3T3 producer cells (Figure 3A). The proteins
migrated slower than the predicted molecular weight of an hbG
monomer due to the presence of N-linked oligosaccharides in
the enzyme (Shipley et al., 1993). hbG displayedmaximal activity
at pH 4.0 but only 2% of maximal activity at pH 7.0 (Figure 3B).
The hbG variants exhibited maximal activity at pH 4.5 with rela-
tively broad pH profiles. The kinetic properties of hbG and vari-
ants were compared at pH 4.5 and pH 7.0 (Table 2). Consistent
with enhanced enzymatic activity of membrane-tethered hbG,
the soluble hbG variants displayed enhanced kcat/Km values at
both pH 4.5 and 7.0 (Figure 3C). At pH 7.0, E1-S and E1-G dis-
played kcat/Km values 4- and 10-fold higher than WT hbG,
whereas S2, S28, and E2-20 variants displayed 20- to 60-fold
enhancements in kcat/Km. Surprisingly, the kcat/Km values of
the S2 and E2-20 enzymes at pH 7.0 were about 2-fold greater
than the kcat/Km of WT hbG at pH 4.5. The dramatic increases
in substrate affinity at acidic and neutral pH explain the overall
enhancement in the activities of the hbG variants. Changes in
amino acid sequence can adversely affect protein stability
(Smith et al., 1997). However, the enzymatic activity of recombi-
nant hbG variants at pH 7.0 was fully retained for at least 2 weeks
Table 1. Amino Acid Substitutions in Selected hbG Variants
Clone
Amino Acid Residue Relative
Activitya159 243 255 518 545 595 599
Wild-type V L L Q T E T 1
E1-S S 21
E1-G G ND
S2 M S L L 65
S28 R S Y F 47
E2-20 Q Q G 116
ND, not determined.
a 3T3 fibroblasts expressing membrane-tethered forms of the indicated
hbG variants were assayed for hbGsurface expression and bG enzymatic
activity. Relative activity of membrane-tethered hbGs was calculated as
the ratio of FL4 (hbG activity)/FL1 (surface hbG expression) at pH 7.0
and normalized to the FL4/FL1 of WT hbG. The substrate was ELF-97
b-D-glucuronide.
Figure 3. pH-Dependent Activities of Soluble hbG Variants
(A) SDS-PAGE of purified WT and variant hbG proteins. Proteins were visual-
ized by staining with Coomassie blue G-250.
(B) The relative enzymatic activities (percentage of maximum activity using
0.5 mM 4-methylumbelliferyl b-D-glucuronide at 37C for 30 min, normalized
to the maximum activity of each clone) of the recombinant enzymes at the in-
dicated pH values are shown (n = 3). Error bars, SD.
(C) Purified hbG proteins were reacted with various concentrations of ELF-97
b-D-glucuronide at pH 4.5 and 7.0 to determine their kinetic constants. The
kcat/Km values at pH 4.5 and 7.0 are shown (n = 3). Error bars, SD.
(D) Percentage of original enzymatic activity retained by hbG proteins after in-
cubation for 14 days at 37C, pH 7.0. The activity was measured by the hydro-
lysis of 0.5 mM 4-methylumbelliferyl b-D-glucuronide at 37C for 30 min. Error
bars, SEM.
Table 2. Kinetic Parameters of Wild-Type and hbG Variants
at pH 4.5 and 7.0
Enzyme
pH 4.5 pH 7.0
Km (mM) kcat (s
1) Km (mM) kcat (s
1)
Wild-type 0.48 ± 0.06 175 ± 17 2.25 ± 0.67 41 ± 6
E1-S 0.052 ± 0.004 117 ± 14 0.39 ± 0.04 31 ± 6
E1-G 0.022 ± 0.002 106 ± 4 0.11 ± 0.01 32 ± 4
S2 0.0081 ± 0.0008 107 ± 7 0.035 ± 0.003 42 ± 4
S28 0.016 ± 0.003 79 ± 3 0.072 ± 0.024 26 ± 3
E2-20 0.0067 ± 0.0005 71 ± 3 0.038 ± 0.005 30 ± 5
Results represent mean values of triplicate determinations ± SD. The
substrate was ELF-97 b-D-glucuronide.
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bility at neutral pH (Figure 3D).
Prodrug Activation by hbG Variants
To determine whether the hbG variants also exhibited enhanced
activity for anticancer glucuronide prodrugs, we incubated EJ
human bladder cancer cells with a constant concentration of
HAMG, a nontoxic glucuronide prodrug of p-hydroxyaniline
mustard, and graded concentrations of WT or mutant hbGs. All
hbG variants hydrolyzed HAMG to cytotoxic drug more effi-
ciently than WT hbG, as demonstrated by enhanced killing of
EJ cancer cells (Figure 4A). The most active S2 variant was
9-fold more effective than WT hbG (EC50 = 2.7 versus 24 mg/ml,
respectively). A similar result was found for SN-38G, which re-
leases the potent topoisomerase I poison SN38 (Rivory, 1996)
upon hydrolysis of the glucuronide moiety (Figure 4B). The
EC50 of WT hbG and the S2 variant were 96 and 8.4 ng/ml,
respectively, representing an 11-fold improvement in prodrug
activation.
DISCUSSION
Alteration of the pH profile of mammalian enzymes by directed
evolution has not been described to our knowledge, likely due
to the difficulty in establishing an appropriate high-throughput
screening system. By combining error-prone PCR with a high-
throughput mammalian cell-surface-tethered screening system,
we successfully generated hbG variants with enhanced activity
over an extended pH range. Importantly, the hbG variants
more effectively hydrolyzed two structurally distinct anticancer
glucuronide prodrugs at neutral pH. Because previous studies
have demonstrated that antibody-hbG immunoenzymes can se-
lectively activate glucuronide prodrugs in tumor xenografts to
produce strong antitumor activity (Bosslet et al., 1994), the
Figure 4. Comparison of Prodrug Activation
by Wild-Type and Mutant hbGs
(A) Prodrug HAMG or SN-38G is hydrolyzed spe-
cifically by hbG to cytotoxic pHAM or SN-38.
(B and C) EJ human bladder cancer cells were in-
cubated with graded concentrations of hbG vari-
ants in RPMI (pH 6.8) containing either (B) 10 mM
HAMG or (C) 100 nM SN-38G for 24 hr. The cells
were further incubated for 24 hr in fresh medium
before incorporation of [3H]thymidine into cellular
DNA was measured.
hbG variants developed here are antici-
pated to further increase the therapeutic
efficacy of glucuronide prodrug therapy.
hbG variants with increased catalytic ac-
tivity at acidic pH may also be of interest
for enzyme replacement therapy of pa-
tients suffering from Sly disease (muco-
polysaccharidosis type VII), especially
for organs, such as the brain, which are
difficult to target (Grubb et al., 2008).
ADEPT and GDEPT are being actively
developed to increase the therapeutic in-
dex of cancer chemotherapy. In ADEPT, an antibody-enzyme
conjugate or fusion protein is allowed to accumulate at cancer
cells before a relatively nontoxic prodrug is administered. Selec-
tive enzymatic hydrolysis of prodrug at cancer cells provides
high localized concentrations of cytotoxic agent in tumors
(Svensson et al., 1995). GDEPT is analogous, except that the
prodrug-activating enzyme is expressed at the tumor site after
viral or nonviral gene transfer of the cancer cells. Most enzymes
employed for ADEPT/GDEPT have been derived from microbial
or viral sources to increase specificity and reduce systemic pro-
drug activation, including b-lactamase (Svensson et al., 1995),
carboxypeptidase G2 (Marais et al., 1997), b-glucuronidase
(Wang, 1992), thymidine kinase (Moolten, 1986), nitroreductase
(Anlezark et al., 1995), and cytosine deaminase (Mullen et al.,
1992). However, nonhuman enzymes can induce robust immune
responses, limiting the number of treatment cycles that can be
administrated to patients (Napier et al., 2000). Several strategies
have been investigated to reduce enzyme immunogenicity. Im-
munosuppressive drugs such as cyclosporine A, cyclophospha-
mide, and deoxyspergualin can decrease or delay the immune
response against foreign proteins (Bagshawe and Sharma,
1996). Immunosuppression, however, besides producing toxic-
ity in patients and hindering the development of antitumor immu-
nity generated by prodrug therapy (Chen et al., 2001), has dis-
played rather limited suppression of strong antibody responses
against bacterial enzymes (Napier et al., 2000; Sharma et al.,
1996). Genetic engineering can be employed to remove immu-
nodominant epitopes from foreign proteins (Spencer et al.,
2002). For example, this technique allowed reduced binding of
preexisting antibodies against an immunodominant epitope in
carboxypeptidase G2 (Mayer et al., 2004). However, the large
antibody repertoire and the heterogeneity of human MHC mole-
cules make this approach technically challenging. Catalytic anti-
bodies that can selectively hydrolyze anticancer prodrugs have
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proach can utilize humanized catalytic antibodies to reduce im-
munogenicity. Highly active catalytic antibodies, however, are
rare. Utilization of human enzyme variants with only a few amino
acid changes represents an alternative approach for clinical
applications.
We successfully isolated hbG variants that displayed greatly
enhanced activity at pH 7. Several factors were important for
successful identification of mutant enzymes. First, high levels
of hbG could be tethered to the surface of 3T3 fibroblasts using
membrane-anchoring domains previously developed in our lab
(Chou et al., 1999; Liao et al., 2001), allowing sensitive detection
of variants with desirable properties. Second, the high infectabil-
ity of fibroblasts allowed generation of large libraries (>107
clones). Third, expression of hbG on mammalian cells allowed
proper glycosylation required for enzymatic activity (Shipley
et al., 1993). Fourth, the reaction pH could be simply controlled
by altering the buffer composition because hbG was tethered
to the cell surface. Finally, utilization of ELF-97 b-D-glucuronide
as the substrate resulted in good retention of fluorescent reac-
tion product in individual clones with little cross contamination
of neighboring cells. ELF-97 b-D-glucuronide appears to display
similar attributes as ELF-97 phosphate, which possesses high
photostability and sensitivity, an unusually large Stokes shift
(170 nm), and precipitates rapidly and remains highly localized
to sites of enzyme activity (Cox and Singer, 1999; Paragas et al.,
2002; Telford et al., 2001). By contrast, we observed high back-
ground and lack of specificity when we screening cell libraries
with fluorescein di-b-D-glucuronide (FDGlcU) or pentafluoroben-
zoylamino fluorescein-di-b-D-glucuronide (PFBFDGlcU) sub-
strates, as they yield a soluble product (fluorescein) which
diffuses rapidly between cells and is therefore not suitable
(Lorincz et al., 1999). Several ELF-97 substrates are commer-
cially available, including ELF-97 N-acetylglucosaminide,
ELF-97 palmitate, ELF-97 acetate, and ELF-97 phosphate (Mo-
lecular Probes). Simple synthesis of analogous substrates
should allow screening by mammalian cell-surface display of al-
most any eukaryotic enzyme that requires secretory-pathway
posttranslational modifications.
Besides allowing good control of reaction conditions, mam-
malian cell-based surface display combined with quantitative
flow cytometric sorting has additional advantages such as (1)
high-throughput (107 variants can be analyzed per hour), quanti-
tative screening; (2) the presence of an endoplasmic reticulum
quality control system to minimize protein-folding errors; (3) effi-
cient surface localization of large oligomeric proteins, such as
hbG (a 380 kDa tetramer); and (4) the opportunity to reduce
host expression bias by using two-dimensional labeling. For
example, we normalized enzyme activity to enzyme surface
levels to ensure that observed enhancements were due to al-
tered catalytic activity rather than to cell-to-cell differences in
enzyme expression levels. Mammalian surface display thus cou-
ples genotype and phenotype while allowing control of selection
conditions for evolution of even large oligomeric proteins within
a living system. These attributes of mammalian surface display
may complement high-throughput screening methods for selec-
tion of enzymes based on bacteria (Becker et al., 2007; Olsen
et al., 2000; Varadarajan et al., 2005) and yeast (Lipovsek
et al., 2007) surface display.
The hbG variants identified in our study include amino acid
substitutions at positions 159, 243, 255, and 518 on the surface
of hbG and positions 545, 595, and 599 near the catalytic pocket
(Figure 5A) (Islam et al., 1999). The catalytic site of hbG is formed
by an a/b TIM barrel consisting of eight alternating parallel
b strands and a helices. The top of the barrel is formed by loops
connecting the C termini of the b strands to the N termini of the
a helices. Two of the loops (b4a4 and b7a7) harbor the catalytic
residues of hbG (E451 and E540, respectively), in common with
many enzymes possessing TIM barrels (Altamirano et al., 2000).
In addition, the b7a7 and b8a8 loops are involved in direct inter-
actions with the corresponding loops in a neighboring monomer
that form a large cavity harboring two active sites (Figure 5B)
(Jain et al., 1996). T599 in the b8a8 loop interacts with the
same amino acid in the neighboring subunit. Single amino acid
Figure 5. Mutations Involved in Enhanced EnzymeActivity at Neutral
pH Values
(A) Amino acid changes in the hbG variants are represented as gray spheres.
(B) Docking model of ELF-97 b-D-glucuronide present in two active sites
formed by interactions of two hbG monomers, colored dark and light blue, re-
spectively. The catalytic E451 and E540 residues are represented in red. ELF-
97 b-D-glucuronide and T545, E595, and T599 residues are represented with
green for carbon atoms, dark blue for nitrogen atoms, red for oxygen atoms,
and gray for hydrogen atoms. The figure was prepared with PyMOL (http://
pymol.sourceforge.net/).
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stantially enhanced substrate affinity. Interestingly, ebG variants
that displayed enhanced catalytic activity against b-D-galacto-
side substrates also incorporated serine or alanine substitutions
at the corresponding threonine (T509 in ebG) (Matsumura and
Ellington, 2001), suggesting that amino acids with smaller side
chains might increase the conformational flexibility of the b7a7
loop and alter substrate affinity. Replacement of T599 with hy-
drophobic amino acids was associated with increased bG activ-
ity at neutral pH, suggesting that alterations in monomer interac-
tions may alter substrate binding. The negatively charged
glutamic acid residue at position 595 was replaced by neutral
or positively charged amino acids in many hbG variants, sug-
gesting that removing a negative charge in the binding pocket
might increase enzyme affinity for the negatively charged
b-D-glucuronide (pKa 2.8).
Clone E2-20, which includes two mutations on the enzyme
surface (L243Q and L255Q), displayed about a 3-fold smaller
Km as compared to E1-G, which shares a common mutation of
T545G. S2 and S28 variants also have mutations in surface
amino acids (V159M and Q518R, respectively). Q518 is present
on the a6 helix of the TIM barrel. Substitution of glutamine with
arginine is unlikely to disrupt the structure of the a helix, suggest-
ing that the effect of this substitution wasmediated by charge ef-
fects. Beneficial mutations present on the surface of hbG are dif-
ficult to explain, due to their distance from the active site.
However, previous studies demonstrated that modifying surface
amino acids can shift the pH profile of enzymes (Russell and
Fersht, 1987). Our results confirm that amino acid substitutions
which are distant from the catalytic cavity can contribute to en-
hanced bG activity.
We examined several approaches to increase the activity of
hbG at neutral pH during the initial phase of this investigation.
In contrast to hbG, ebG catalyzes the hydrolysis of glucuronides
with high efficiency at pH 7.0. However, the structure and amino
acids in the catalytic pocket of ebG and hbG are nearly identical,
hindering rational design of hbG variants by comparison with
ebG. On the other hand, molecular modeling indicated that the
surface charge of ebG ismore negative than hbG (Figure S2). Dif-
ferences in the surface charge of enzymes may affect the pKa of
catalytic amino acids, resulting in alterations in enzymatic pH op-
tima (Russell and Fersht, 1987). Acid-base catalysis generally re-
quires two carboxy side chains, one which is protonated and the
other ionized. In hbG, E451 acts as an acid-base whereas E540
functions as a nucleophile (Islam et al., 1999). We hypothesized
that reducing the surface charge of hbG might increase the pKa
of E451, thereby maintaining the carboxy side chain in the acid
form at elevated pH levels. Positive and neutral amino acids
with side chains predicted to project away from the surface of
hbG were therefore substituted with negatively charged amino
acids. However, altering the surface charge had minimal effect
on the pH optimum of hbG (Figure S3). In addition, all mutants
displayed at least 85% reductions in catalytic activity (results
not shown). In another approach, we attempted to identify amino
acids important in controlling the pH profile of hbG by employing
random chimeragenesis on transient templates (RACHITT) to
shuffle ebGand hbGgenes (Coco et al., 2002).We could not suc-
cessfully shuffle these genes, however, likely due to their low
overall homology of 50.7%.
In summary, we developed a mammalian cell-surface display
approach to evolve hbG variants with enhanced capability to hy-
drolyze anticancer glucuronide prodrugs at the physiological
conditions of the tumor. These hbG variants are anticipated to
improve the efficacy of ADEPT and GDEPT and may allow mul-
tiple treatment rounds due to their low immunogenicity. More-
over, this technology may be applied on other enzymes and
other selection conditions, as mammalian expression libraries
of membrane-tethered enzymes allow straightforward in vitro
evolution of enzyme properties.
SIGNIFICANCE
Many proteins require posttranslational modifications, such
as glycosylation, to correctly fold and display biological ac-
tivity. Development of high-throughput screening methods
for identification of glycoproteins with altered properties
will facilitate elucidation of protein structure-function rela-
tionships as well as allow isolation of improved proteins
for novel biotechnological andmedical applications. Toward
this goal, we developed a high-throughput screening proce-
dure for enzymatic activity based on tethered enzyme
expression and stable retention of fluorescent reaction
products in mammalian cells. A key advantage of this meth-
odology is the ability to precisely control screening condi-
tions such as reaction pH. Furthermore, fluorescence-acti-
vated cell sorting allows screening of 107 enzyme variants
per hour and reduces protein expression bias by simple
quantitative measurement of surface expression levels. We
demonstrated the utility of this screening procedure by iso-
lating variants of human b-glucuronidase, a tetrameric gly-
coprotein normally present in lysosomes, that displayed sig-
nificantly enhanced enzymatic activity at pH 7.0. The human
b-glucuronidase variants isolated in our study are antici-
pated to extend the utility of selective cancer therapy by glu-
curonide prodrug treatment due to low immunogenicity in
humans and enhanced catalytic activity at the physiological
pH present in human tumors. The screening methodology
described here should greatly facilitate investigation and
modification of eukaryotic enzymes requiring posttransla-
tional modifications for biological activity.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
ELF-97 alcohol and ELF-97 b-D-glucuronide were fromMolecular Probes (Eu-
gene, OR, USA). 4-methylumbelliferyl b-D-glucuronide and CPT-11 were from
Sigma-Aldrich (St. Louis, MO, USA). Biotinylated anti-HA antibody was from
Vector Laboratories (Burlingame, CA, USA). Rhodamine-conjugated streptavi-
din and goat anti-rat FITC conjugate were from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA). Mouse anti-hbG mAb 7G8 and rat anti-
mouse bG (mbG) mAb 7G7 have been described (Chen et al., 2007). 7G8
was directly labeled with FITC as described (Goding, 1976). HAMG was syn-
thesized as described (Roffler et al., 1991). SN-38G was purified by HPLC
from the urine of mice treated with CPT-11.
Cells
BALB/3T3 fibroblasts (CCL-163; ATCC,Manassas, VA, USA) andCT26murine
colon carcinoma cells (ATCC CRL-2638) were cultured in DMEM (4.5 g/l glu-
cose) supplemented with 10% bovine serum, 2.98 g/l HEPES, 2 g/l NaHCO3,
100 U/ml penicillin, and 100 mg/ml streptomycin. EJ human bladder carcinoma
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ments. CT26 and EJ cell lines expressing membrane-tethered mbG on their
surface have been described (Chen et al., 2007). All cells were free of myco-
plasma as determined by PCR.
Error-Prone PCR
A silent mutation was made to change cytosine to guanidine at position 411 of
the hbG gene in pLNCX-hbG-eB7 (Chen et al., 2007) to remove an internal SalI
site. The resulting vector, pLNCX-hbGs-eB7, was employed as a template for
error-prone PCR (Cadwell and Joyce, 1992) using primer P1 (50-TATGCTGGG
GCC CAG CCG GCC-30 ), which contains part of the HA epitope at the 50 end
and an SfiI restriction site at the 30 end (underlined), and primer P2 (50-CTG
AGA TGA GTT TTT GTT CGT CGA C-30), which contains part of the myc epi-
tope at the 50 end and a SalI restriction site at the 30 end (underlined). Muta-
genic buffer (8 mM dCTP, 8 mM dTTP, 48 mM MgCl2, 5 mM MnCl2) (Matsu-
mura and Ellington, 2001) was added (1.25 or 2.5 ml) to each 50 ml PCR
reaction using 5 units Taq polymerase (Takara, Shiga, Japan) for amplification.
The PCR product was digested with SfiI and SalI enzymes, ligated into the
same sites in pLNCX-hbGs-eB7, and transformed into DH5a competent cells
by electroporation. Transformed bacteria were selected on 15 cm carbenicil-
lin-containing LB agar plates for 16 hr at 37C. Colonies from multiple plates
were collected and expanded in carbenicillin-containing LB medium and
then amplified by addition of 170 mg/ml chloramphenicol. Plasmid DNA from
each library was purified by centrifugation in a CsCl-ethidium bromide density
gradient at 60,000 rpm in a Ti 70.1 rotor at 4C for 24 hr using a Beckman
Optima L-90K ultracentrifuge (Beckman Coulter, Fullerton, CA, USA).
Retroviral Transduction
To generate stable cell libraries or His-tagged soluble hbG producer cells,
plasmid DNA was cotransfected with pVSV-G (Clontech, Mountain View,
CA, USA) into GP293 cells (Clontech) to produce recombinant retroviral parti-
cles. Two days after transfection, the culture medium was filtered, mixed with
8 mg/ml polybrene, and added to 3T3 fibroblasts. Stable cell lines were se-
lected in medium containing 0.5 mg/ml G418 (Calbiochem, San Diego, CA,
USA).
Selection of High-Activity hbG Cells
3T3 cell libraries were screened by fluorescence-activated cell sorting (FACS).
Typically, 107 3T3 cells expressing membrane-tethered hbG variants were
washed and suspended in 0.4 ml BSA/HBSS (5.4 mM KCl, 0.3 mM Na2HPO4,
0.4 mM KH2PO4, 4.2 mM NaHCO3, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.6 mM
MgSO4, 137 mM NaCl, 5.6 mM D-glucose [pH 7.4]) containing 0.5% BSA
and 20 mg/ml 7G8-FITC for 30 min at 4C. Cells were then washed and incu-
bated with 25, 50, or 100 mM ELF-97 b-D-glucuronide at defined pH values
in 50 mM bis-Tris, 25 mM glucose, 85.6 mM NaCl, 5.4 mM KCl, 0.6 mM
MgSO4, 1.3 mM CaCl2 at 37
C for 10 min. The cells were washed with
ice-cold 0.5% BSA/HBSS and suspended in 0.5% BSA/HBSS containing
5 mg/ml propidium iodide (Sigma). Cells were sorted on a FACSVantage
DiVa (Becton Dickinson, Franklin Lakes, NJ, USA) equipped with an Enterprise
IIC argon laser for dual excitation at 488 and 351–364 nm. Dead cells (propi-
dium iodide positive, high FL3 fluorescence) were gated out before 7G8-
FITC immunofluorescence was detected at excitation/emission wavelengths
of 488/515 nm (FL1) and ELF-97 alcohol was detected at excitation/emission
wavelengths of 351/530 nm (FL4). In later experiments, cells were sorted twice
each round; cells exhibiting the highest 10% activity were collected and then
immediately sorted again to collect the cells displaying the highest 5% activity
(representing 0.5% of the total starting population). Double sorting greatly de-
creased contamination with low-activity cells. The sorted cells were cultured
for 4–10 days for sequential rounds of cell sorting or RNA extraction. Flow
cytometer data were analyzed using Flowjo (Tree Star, Ashland, OR, USA).
DNA Shuffling
Variant hbG genes were recovered by RT-PCR from the cells collected after
three rounds of FACS. hbG DNA (1 mg) was digested with 0.025 U of DNase I
(Takara) in 25 ml of 50 mM Tris-HCl (pH 7.4), 1 mM MgCl2 for 11 min at
25C. The reaction was quenched by adding 5 ml of 0.5 M EDTA. DNA frag-
ments ranging from 100 to 300 bases on a 1% agarose gel were reassembled
in 35 cycles of primerless PCR (Stemmer, 1994). The full-length recombinant
products, amplified in a standard PCR reaction with P1 and P2 primers,
were cloned in pLNCX-hbGs-eB7 to create a new 3T3 cell library.
Saturation Mutagenesis
To generate randomized mutations at amino acid positions 545, 595, and 599
in hbG, two rounds of site-directed mutagenesis were performed using the
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
All possible amino acids were introduced at amino acid position 545 with
primers P3 (50-CGA GTA TGG AGC AGA ANN SAT TGC AGG GTT TCA CCA
GGA TCC-30) and P4 (50-GGA TCC TGG TGA AAC CCT GCA ATS NNT TCT
GCT CCA TAC TCG-30), where N represents G, A, T, or C, and S represents
G or C. A second round of site-directed mutagenesis was performed with
primers P5 (50-GGA ATT TTG CCG ATT TCA TGA CTN NSC AGT CAC CGN
NSA GAG TGC TGG GGA ATA AAA AGG GG-30) and P6 (50-CCC CTT TTT
ATT CC CAG CAC TCT SNN CGG TGA CTG SNN AGT CAT GAA ATC GGC
AAA ATT CC-30) to further introduce all possible amino acids at positions
595 and 599 of hbG. The resulting saturation mutagenesis DNA library was
ligated into the SfiI and SalI sites present in pLNCX-hbGs-eB7 and employed
to generate a 3T3 cell library.
Purification of Recombinant hbG Proteins
Recombinant His-tagged hbG was purified from stable 3T3 fibroblast lines as
described (Wu et al., 2004).
Enzyme Assays
The pH-dependent enzyme activities of recombinant hbG variants were mea-
sured in triplicate with 0.1 mM ELF-97 b-D-glucuronide at 37C for 30 min at
defined pH ranging from 3 to 10 in bG reaction buffer (50 mM bis-Tris,
50 mM triethanolamine, 100 mM acetic acid, 0.1% BSA). The reaction was
quenched by adding an equal volume of stop buffer (2 M Tris-HCl, 0.8 M so-
dium bicarbonate [pH 8]). The fluorescence of ELF-97 alcohol and 4-methyl-
umbelliferone was measured in a Gemini EM microplate spectrofluorometer
(Molecular Devices, Sunnyvale, CA, USA) at excitation/emission wavelengths
of 355/555 nm. Kinetic values for hbG substrate hydrolysis were determined by
diluting ELF-97 b-D-glucuronide (2 mM) in pH 4.5 or pH 7.0 bG reaction buffer
1:1 with defined concentrations of hbG in 200 ml. Fluorescence was immedi-
ately measured under thermal control at 37C for 8–10 min. The measurement
was repeated using the same amount of enzyme for different concentrations of
substrate in an optimal range. The acquired readings were converted to prod-
uct concentration by preestablished standard curves. Double reciprocal plots
were used to determine Km and kcat. Kinetic assays were performed at least
three times and mean values were calculated. The stability of recombinant
hbG variants was assayed by measuring their enzymatic activity at time
0 and again after incubating 5 mg of purified enzyme in PBS (containing
0.5 mg/ml BSA) at 37C for 14 days. The enzymatic activities of the hbG
variants were measured in triplicate with 0.5 mM4-methylumbelliferyl b-D-glu-
curonide at 37C for 15 min at pH 7.0 in bG reaction buffer. The reaction was
terminated by adding an equal volume of stop buffer (1 M glycine, 0.5 M so-
dium bicarbonate [pH 11]) and the fluorescence was measured at excitation/
emission wavelengths of 355/460 nm in a microplate spectrofluorometer.
[3H]Thymidine Incorporation Assay
Defined concentrations of purified recombinant hbG were added with 10 mM
p-hydroxyaniline mustard glucuronide (HAMG) or 100 nM SN-38 glucuronide
(SN-38G) to 5000 EJ human bladder cancer cells in 200 ml of complete medium
at pH 6.8 for 24 hr. The cells were washed and incubated in fresh medium for
24 hr and then pulsed for 16 hr with [3H]thymidine (1 mCi/well). The cells were
harvested and the radioactivity was measured in a TopCount microplate scin-
tillation counter (Packard, Meriden, CT, USA). Results are expressed as per-
cent inhibition of [3H]thymidine incorporation into cellular DNA in comparison
to untreated cells.
Molecular Modeling
To examine potential interactions of ELF-97 b-D-glucuronide with mutated
amino acids in hbG variants, the X-ray crystal structure of ebG with glucaro-
1,5-lactone in the active site (unpublished data) was employed as a template
to position the glucuronide group of ELF-97 b-D-glucuronide. ELF-97
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tion of two hbG monomers using Molegro 2.2.0 (Aarhus, Denmark).
Statistical Analysis
Statistical significance of differences between mean values was estimated by
Excel (Microsoft, Redmond,WA, USA) using the independent t test for unequal
variances. P values of less than 0.05 were considered to be statistically signif-
icant.
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